Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca’s eplontersen, an investigational therapy for the treatment of